机构：[1]Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.神经科系统神经内科首都医科大学宣武医院[2]Evidence-Based Medicine Center, Xuanwu Hospital of Capital Medical University, Beijing, China.首都医科大学宣武医院[3]Department of Epidemiology and Biostatistics, School of Public Health, Capital Medical University, Beijing, China.[4]Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Haikou, China.[5]Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany.[6]Institute of Biomedical Engineering, School of Information and Communication Engineering, Shanghai University, Shanghai, China.[7]German Center for Neurodegenerative Disease, Clinical Research Group, Bonn, Germany.[8]German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.[9]Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.[10]Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, China.[11]National Clinical Research Center for Geriatric Disorders, Beijing, China.
Subjective cognitive decline (SCD) is considered as the first symptomatic manifestation of Alzheimer's disease (AD), which is also affected by different cultural backgrounds. Establishing cross-cultural prediction models of SCD is challenging.To establish prediction models of SCD available for both the Chinese and European populations.In this project, 330 SCD from China and 380 SCD from Germany are intended to be recruited. For all participants, standardized assessments, including clinical, neuropsychological, apolipoprotein E (APOE) genotype, blood, and multi-parameter magnetic resonance imaging (MRI) at baseline will be conducted. Participants will voluntarily undergo amyloid positron emission tomography (PET) and are classified into amyloid-β (Aβ) positive SCD (SCD+) and Aβ negative SCD (SCD-). First, baseline data of all SCD individuals between the two cohorts will be compared. Then, key features associated with brain amyloidosis will be extracted in SCD+ individuals, and the diagnosis model will be established using the radiomics method. Finally, the follow-up visits will be conducted every 12 months and the primary outcome is the conversion to mild cognitive impairment or dementia. After a 4-year follow-up, we will extract factors associated with the conversion risk of SCD using Cox regression analysis.At present, 141 SCD from China and 338 SCD from Germany have been recruited. Initial analysis showed significant differences in demographic information, neuropsychological tests, and regional brain atrophy in SCD compared with controls in both cohorts.This project may be of great value for future implications of SCD studies in different cultural backgrounds.ClinicalTrials.gov, NCT04696315. Registered 3 January 2021.
基金：
This article was supported by National Natural Science Foundation of China (Grant 61633018,82020108013, 81801052).
第一作者机构：[1]Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
通讯作者：
通讯机构：[1]Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.[4]Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Haikou, China.[5]Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany.[7]German Center for Neurodegenerative Disease, Clinical Research Group, Bonn, Germany.[8]German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.[9]Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.[10]Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, China.[11]National Clinical Research Center for Geriatric Disorders, Beijing, China.[*1]Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China, 100053[*2]Department of Psychiatry, Medical Faculty, University of Cologne, 50924 Cologne, Germany[*3]Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China, 100053
推荐引用方式(GB/T 7714)：
Sheng Can,Yang Kun,He Beiqi,et al.Cross-Cultural Longitudinal Study on Cognitive Decline (CLoCODE) for Subjective Cognitive Decline in China and Germany: A Protocol for Study Design.[J].JOURNAL OF ALZHEIMERS DISEASE.2022,87(3):1319-1333.doi:10.3233/JAD-215452.
APA：
Sheng Can,Yang Kun,He Beiqi,Li Taoran,Wang Xiaoqi...&Han Ying.(2022).Cross-Cultural Longitudinal Study on Cognitive Decline (CLoCODE) for Subjective Cognitive Decline in China and Germany: A Protocol for Study Design..JOURNAL OF ALZHEIMERS DISEASE,87,(3)
MLA：
Sheng Can,et al."Cross-Cultural Longitudinal Study on Cognitive Decline (CLoCODE) for Subjective Cognitive Decline in China and Germany: A Protocol for Study Design.".JOURNAL OF ALZHEIMERS DISEASE 87..3(2022):1319-1333
